- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.
Juno Therapeutics CEO Hans Bishop tells TheStreet Juno is focused on the better treatment of patients with cancer.
U.S. drugmaker Eli Lilly and French pharmaceutical company Adocia agree to a $570 million deal to develop a fast-acting insulin.
Stephanie Link picks baskets of stocks that diversified within the sector itself and says that will be applied to her 2015 Healthcare picks.
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
U.S. stock futures rise after the Dow sees its largest advance since November 2011; Nike beats earnings forecasts but future orders are light; MetLife is deemed 'systemically important.'
Rite Aid shares spiked more than 12% after the drugstore chain boosted its guidance for the year. Here's what analysts said.
Congrats to David Schenkein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
U.S. stock futures rise as Fed says it will remain 'patient' on raising interest rates; Snapchat's business plans unveiled in Sony hack; Oracle profit tops estimates.
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
U.S. stock futures rise ahead of the Fed's policy announcement; GE sees 2015 profit pressured by decline in oil prices; Baidu confirms investment in Uber.
Auspex is expected to seek U.S. approval for SD-809 next year.
Olympus Corporation has fully recovered from its 2011 financial scandal and is firing on all cylinders, said the company's Americas President Nacho Abia.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV